2025 Global Automatic Nucleic Acid Extraction Instrument Market Revenue Opportunities Report
Description
The 2025 Global Automatic Nucleic Acid Extraction Instrument Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Automatic Nucleic Acid Extraction Instrument Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Automatic Nucleic Acid Extraction Instrument Market are QIAGEN N.V., Thermo Fisher Scientific Inc., Roche Diagnostics, and Promega Corporation. QIAGEN leads the market with an estimated 22-26% share, offering a broad portfolio of both manual and automated nucleic acid extraction kits used extensively in clinical diagnostics and molecular testing worldwide. Thermo Fisher holds about 18-22% market share, specializing in high-throughput magnetic bead-based extraction systems with enhanced automation and cloud integration for research and forensic applications. Roche, with 14-18% share, focuses on automated, high-fidelity extraction systems tailored for molecular pathology and infectious disease labs. Promega, accounting for 8-12%, provides user-friendly, reagent-preloaded nucleic acid purification platforms favored in personalized medicine and oncology research.
These companies drive innovation through frequent product launches and strategic expansions. QIAGEN recently expanded its QIAamp® and EZ1® Advanced XL platforms for high-throughput diagnostics with integration into laboratory information management systems. Thermo Fisher upgraded its MagMAX™ and KingFisher™ systems, enhancing throughput and automation capabilities. Roche released the updated MagNA Pure 96 system, designed for simultaneous high-volume DNA/RNA extraction in clinical settings with minimal contamination risk. Promega introduced the Maxwell® HT system with ready-to-use reagents tailored for scalable and versatile genomic workflows, reflecting ongoing market competition and a focus on meeting increasing demand for efficient and reliable nucleic acid extraction technologies globally.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Automatic Nucleic Acid Extraction Instrument Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Automatic Nucleic Acid Extraction Instrument Market are QIAGEN N.V., Thermo Fisher Scientific Inc., Roche Diagnostics, and Promega Corporation. QIAGEN leads the market with an estimated 22-26% share, offering a broad portfolio of both manual and automated nucleic acid extraction kits used extensively in clinical diagnostics and molecular testing worldwide. Thermo Fisher holds about 18-22% market share, specializing in high-throughput magnetic bead-based extraction systems with enhanced automation and cloud integration for research and forensic applications. Roche, with 14-18% share, focuses on automated, high-fidelity extraction systems tailored for molecular pathology and infectious disease labs. Promega, accounting for 8-12%, provides user-friendly, reagent-preloaded nucleic acid purification platforms favored in personalized medicine and oncology research.
These companies drive innovation through frequent product launches and strategic expansions. QIAGEN recently expanded its QIAamp® and EZ1® Advanced XL platforms for high-throughput diagnostics with integration into laboratory information management systems. Thermo Fisher upgraded its MagMAX™ and KingFisher™ systems, enhancing throughput and automation capabilities. Roche released the updated MagNA Pure 96 system, designed for simultaneous high-volume DNA/RNA extraction in clinical settings with minimal contamination risk. Promega introduced the Maxwell® HT system with ready-to-use reagents tailored for scalable and versatile genomic workflows, reflecting ongoing market competition and a focus on meeting increasing demand for efficient and reliable nucleic acid extraction technologies globally.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
